← Eichor
Condition: Early Stage Triple Negative Breast Carcinoma Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Early Stage Triple Negative Breast Carcinoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer
Phase 4 · 34 location(s) · Fudan University · NCT04790305Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKK
Phase 2 · 9 location(s) · Swiss Cancer Institute · NCT06358573Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Canc
Phase 1 · 4 location(s) · Emory University · NCT06324240Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBC
Phase 2 · 44 location(s) · UNICANCER · NCT06078384Pre-operative SABR With and Without Caloric Restriction for Early Stage Breast Cancer
NA · 1 location(s) · Thomas Jefferson University · NCT04959474Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer
Phase 2 · 1 location(s) · Stanford University · NCT04768426SBRT Combined With PD-1 Inhibitor and Chemotherapy in Early-stage TNBC
Phase 3 · 1 location(s) · West China Hospital · NCT06627712Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
Phase 2 · 1 location(s) · Fudan University · NCT05582499FMD and Neoadjuvant Chemo-immunotherapy in TNBC
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT07378306Evaluating and Monitoring Immune and Clinical Responses in Early-Stage Triple Negative Breast Cancer Undergoing Neoadjuv
Phase N/A · 1 location(s) · Emory University · NCT05877859A Study of QL1706 Combined With Short-Cycle Anthracyclines or Taxanes for the Treatment of Early-Stage TNBC
Phase 1 · 1 location(s) · Xijing Hospital · NCT07178171A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Phase 3 · 317 location(s) · Merck Sharp & Dohme LLC · NCT06966700Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stag
Phase 2 · 17 location(s) · Merck Sharp & Dohme LLC · NCT06797635Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer
Phase 2 · 2 location(s) · Baylor Breast Care Center · NCT05020860I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Phase 2 · 42 location(s) · QuantumLeap Healthcare Collaborative · NCT01042379A Study to Explore Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of Novel Therapeutics in Patients Wit
Phase 1/Phase 2 · 1 location(s) · Gustave Roussy, Cancer Campus, Grand Paris · NCT06508216Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT07407920Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer
Phase 2 · 5 location(s) · Sun Yat-sen University · NCT06768931PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC
Phase 2 · 2 location(s) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · NCT06245889Nab-P+Cb+PD1 Inhibitors as Neoadjuvant Therapy for Early TNBC
Phase 2 · 1 location(s) · Henan Cancer Hospital · NCT06817525EvoLution of Neoadjuvant TreatMent in 'Triple-negative' or 'HER-2-positive' Breast Cancer Diagnosed in the EaRly Phase
Phase N/A · 29 location(s) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · NCT06894173Early Detection of Triple Negative Breast Cancer Relapse (CUPCAKE)
NA · 13 location(s) · Institut Curie · NCT06225505Pilot Study of Aerobic Exercise During Immune Checkpoint Inhibitor Therapy in Early-Stage TNBC
NA · 1 location(s) · M.D. Anderson Cancer Center · NCT07216495TIL-Driven De-escalated Chemotherapy in Stage I-II TNBC
Phase 2 · 5 location(s) · D'Or Institute for Research and Education · NCT07074106Personalizing the Use of Pembrolizumab for Patients Who Have a Strong Response in Early Triple Negative Breast Cancer
Phase 3 · 2 location(s) · UNICANCER · NCT06606730DecipHER Trial - DC1 Tx for Early-Stage TNBC and ER Low Positive Breast Cancer
Phase 1 · 1 location(s) · H. Lee Moffitt Cancer Center and Research Institute · NCT05504707Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Maligna
Phase N/A · 14 location(s) · Tempus AI · NCT07211178Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After
Phase 3 · 842 location(s) · Alliance for Clinical Trials in Oncology · NCT05812807Neoadjuvant Chemotherapy With or Without GnRH Agonist for Premenopausal Triple-negative Early Breast Cancer Patients
Phase 2 · 1 location(s) · National Taiwan University Hospital · NCT06225284Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform
Phase N/A · 3 location(s) · Mayo Clinic · NCT06349642
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.